Shareholders Corner - JB Pharma

Close

Investor

Information

Shareholders' Corner

Latest Disclosures
Disclosures under Regulation 46 of SEBI (LODR)
Code of Conduct & Policies

Disclosure of Material Event – Allotment of Equity Shares on exercise of Stock options pursuant to ESOP Scheme_18.12.2024

View / Download

Disclosure of Material Event – Allotment of Equity Shares on exercise of Stock options pursuant to Employee Stock Option_06.12.2024

View / Download

Disclosure of Material Event – Allotment of Equity Shares on exercise of Stock options pursuant to ESOP Scheme_20.11.2024

View / Download

Q2 FY25 Earnings Call Transcript

View / Download

Audio recording of earnings conference call_07.11.2024

View / Download

Q2 FY25 Investor Presentation

View / Download

Financial Information

CEO's Desk

We believe that we are BIG enough to create a positive impact for patients and healthcare providers, yet small enough to still care.

Annual Return

List of shareholder 2023

Annual Return as on 31.03.2023

List of shareholders as on 31.03.2022

Annual Return as on 31.03.2022

List of Shareholders as on 31.03.2021

Board Committees

Composition of committees of the board of directors 09.07.2024

Business Responsibility and Sustainability Report

Business Responsibility and Sustainability Report 2023-24

Business Responsibility and Sustainability Report 2022-23

Business Responsibility Report 2021-22

Business Responsibility Report 2020-21

Business Responsibility Report 2019-20

Buy-back of Equity Shares

ESOP disclosure for the year ended 31.03.2024

ESOP disclosure for the year ended 31.03.2023

SE allotment 13/09/2022

ESOP disclosure for the year ended 31.03.2022

ESOP disclosure for the year ended 31.03.2021

Contact Details of KMP

Contact details of KMP 12.07.2024

Credit Rating

Credit Rating

CSR Disclosures

Annual Report on CSR for the financial year 2023-24

CSR Projects FY 2023-24

Annual Report on CSR for the financial year 2022-23

CSR Projects FY 2022-23

Annual Report on CSR for the financial year 2021-22

Environmental Compliances

MOEF half yearly Compliance report

ESOP Disclosures

ESOP disclosure for the year ended 31.03.2024

ESOP disclosure for the year ended 31.03.2023

SE allotment 13/09/2022

ESOP disclosure for the year ended 31.03.2022

ESOP disclosure for the year ended 31.03.2021

Familiarisation Programme for IDs

Details of Familiarisation Programme for Directors

General Meetings/Postal Ballot

AGM Voting Results FY24-25

Disclosure of Material Event – Proceedings of AGM

Newspaper advertisement for AGM Notice FY 2023-24

AGM Notice FY23-24

Postal Ballot Voting Results FY23-24

Prior public notice for AGM through VC_OAVM FY 2023-24

Postal Ballot Notice

Postal Ballot Voting Results FY23-24 21.12.2023

Postal Ballot Voting Results 08.04.2024

Newspaper advertisment for Postal Ballot FY 2023-24 09.03.2024

Postal Ballot Notice 06.03.2024

Newspaper advertisement for Postal Ballot FY23-24

Postal Ballot Notice 07.11.2023

Transcript of 47th AGM

Disclosure of Material Event – Proceedings of AGM

AGM Voting Results FY22-23

Newspaper advertisement for AGM Notice FY 2022-23

AGM Notice FY22-23

Prior public notice for AGM through VC_OAVM FY22-23

AGM Voting Results FY23-24

Information relating to Investor Service Requests

Important communication regarding TDS on Final Dividend FY 2023-24

Form 15G

Form 15H

Declaration under Rule 37BA

Important communication regarding TDS on Interim Dividend FY 2023-24

Form ISR 3 (2023-24)

Form ISR 2 (2023-24)

Form ISR 1 (2023-24)

Form SH-14

Form SH-13

Intimation to Stock Exchanges

Related Party Transactions for the half year ended September 30, 2024

Newspaper advertisement of extract of unaudited consolidated financial results for quarter ended on September 30, 2024

Notice of Board Meeting for Q2 Results

Intimation of schedule of Analysts_Institutional Investors meet 06.09.2024

Intimation of schedule of Analysts_Institutional Investors meet 03.09.2024

Letter of Appointment of IDs

Letter of Appointment of IDs

Material Information/Event

Disclosure of Material Event – Allotment of Equity Shares on exercise of Stock options pursuant to ESOP Scheme_18.12.2024

Disclosure of Material Event – Allotment of Equity Shares on exercise of Stock options pursuant to Employee Stock Option_06.12.2024

Disclosure of Material Event – Allotment of Equity Shares on exercise of Stock options pursuant to ESOP Scheme_20.11.2024

Q2 FY25 Earnings Call Transcript

Audio recording of earnings conference call_07.11.2024

Shareholding Pattern

Statement showing holding of securities and shareholding pattern – Q2 2024-25

Statement showing holding of securities and shareholding pattern – Q2 2024-25

Statement showing holding of securities and shareholding pattern – Q1 2024-25

Statement showing holding of securities and Shareholding pattern – Q4 2023-24

Statement showing holding of securities and shareholding pattern – Q3 2023-24

Statement showing holding of securities and shareholding pattern – Q2 2023-24

Statement showing holding of securities and shareholding pattern – Q1 2023-24

Statement showing holding of securities and shareholding pattern – Q4 2022-23

Statement showing holding of securities and shareholding pattern – Q3 2022-23

Statement showing holding of securities and shareholding pattern – Q2 2022-23

Statement showing holding of securities and shareholding pattern – Q1 2022-23

Statement showing holding of securities and shareholding pattern – Q4 2021-22

Statement showing holding of securities and shareholding pattern – Q3 2021-22

Statement showing holding of securities and shareholding pattern – Q2 2021-22

Statement showing holding of securities and shareholding pattern-Q1 2021-22

Subsidiary Companies Financials

Accounts of subsidiary Unique Pharmaceutical Laboratories FZE, Dubai for the year ended on March 31, 2024

Accounts of subsidiary OOO Unique Pharmaceutical Laboratories, Russia for the year ended on March 31, 2024.

Accounts of the subsidiary Biotech Laboratories (Pty.) Ltd., South Africa for the year ended on March 31, 2024

Accounts of subsidiary Unique Pharmaceutical Laboratories FZE, Dubai for the year ended on March 31, 2023

Accounts of subsidiary OOO Unique Pharmaceutical Laboratories, Russia for the year ended on March 31, 2023

Accounts of subsidiary Biotech Laboratories (Pty.) Ltd., South Africa for the year ended on March 31, 2023

Accounts of subsidiary Biotech Laboratories (Pty.) Ltd., South Africa for the year ended on March 31, 2022

Accounts of subsidiary OOO Unique Pharmaceutical Laboratories, Russia for the year ended on March 31, 2022

Accounts of subsidiary Unique Pharmaceutical Laboratories FZE, Dubai for the year ended on March 31, 2022

Accounts of subsidiary OOO Unique Pharmaceutical Laboratories, Russia for the year ended on March 31, 2021

Accounts of subsidiary Unique Pharmaceutical Laboratories FZE, Dubai for the year ended on March 31, 2021

Accounts of subsidiary Biotech Laboratories (Pty.) Ltd., South Africa for the year ended on March 31, 2021

Accounts of subsidiary Unique Pharmaceutical Laboratories FZE, Dubai for the year ended on March 31, 2020

Accounts of subsidiary OOO Unique Pharmaceutical Laboratories, Russia for the year ended on March 31, 2020

Accounts of subsidiary Biotech Laboratories (Pty.) Ltd., South Africa for the year ended on March 31, 2020

Accounts of subsidiary Unique Pharmaceutical Laboratories FZE, Dubai for the year ended on March 31, 2019

Accounts of subsidiary OOO Unique Pharmaceutical Laboratories, Russia for the year ended on March 31, 2019

Accounts of subsidiary Biotech Laboratories (Pty.) Ltd., South Africa for the year ended on March 31, 2019

Accounts of subsidiary Unique Pharmaceutical Laboratories FZE, Dubai for the year ended on March 31, 2018

Accounts of subsidiary LLC Unique Pharmaceutical Laboratories, Russia for the year ended on March 31, 2018

Transfer of shares to IEPF

Statement of Shares liable to transfer to IEPF

Notice in respect of equity shares liable to transfer to IEPF during 2024-25

Notice in respect of equity shares liable to transfer to IEPF during 2023-24

Notice in respect of equity shares liable to transfer to IEPF during 2022-23

Statement of shares transferred to IEPF during FY 2023-24

Unclaimed Dividend

Statement of Shareholders for Unclaimed Final Dividend 2021-22 transferred to Unpaid dividend account

Statement of Shareholders for Unclaimed Interim Dividend 2021-22 transferred to Unpaid dividend account

Statement of Shareholders for Unclaimed Final Dividend 2020-21 transferred to Unpaid dividend account

Statement of Shareholders for Unclaimed Interim Dividend 2020-21 transferred to Unpaid dividend account

Unclaimed Dividend as on 31.03.2020

Financial Information

CEO's Desk

We believe that we are BIG enough to create a positive impact for patients and healthcare providers, yet small enough to still care.

Code of practices and procedures for fair disclosure of Unpublished Price Sensitive Information

View / Download

Code of Conduct for Board of Directors and Senior Management Personnel

View / Download

Policy for determining material subsidiary

Whistle Blower Policy

Complaint Response Plan Policy

Code of Conduct

Policy on dealing with related party transactions

Corporate Social Responsibility Policy

Web archival policy

Business Responsibility Policy

Risk Management Policy

Board Diversity Policy

Dividend Distribution Policy

Policy On Directors’ Appointment and Remuneration

Materiality of Event

Financial Information

CEO's Desk

We believe that we are BIG enough to create a positive impact for patients and healthcare providers, yet small enough to still care.

IR & Shareholder Contact

For Shareholders:
Mr. Sandeep Phadnis
Neelam Centre, ‘B’ Wing, 4th floor,
Hind Cycle Road, Worli,
Mumbai 400 030 India.

Tel No. 91-22-2439 5200 / 2439 5500 Fax No. 91-22-2431 5331 / 2431 5334 Email: investorelations@jbpharma.com

For transfer/transmission of shares:
Datamatics Business Solutions Ltd.
Plot No. A 16 & 17, Part B Cross Lane,
MIDC, Andheri (East), Mumbai 400 093

Contact Person: Mr. Satish Patil
Tel No: (022) 6671 2001-06
Fax No. (022) 6671 2011
Email: investorquery@datamaticsbpm.com

Nodal Officer for the purpose of coordination with IEPF authority:
Mr. Sandeep Phadnis
Neelam Centre, ‘B’ Wing, 4th floor,
Hind Cycle Road, Worli,
Mumbai 400 030 India.

Tel No. 91-22-2439 5200 / 2439 5500 Fax No. 91-22-2431 5331 / 2431 5334
Email: investorelations@jbpharma.com